QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.

doi:10.1016/j.jid.2020.08.018

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.

The Journal of investigative dermatology - 1 Apr 2021

Bornert Olivier, Hogervorst Marieke, Nauroy Pauline, Bischof Johannes, Swildens Jim, Athanasiou Ioannis, Tufa Sara F, Keene Douglas R, Kiritsi Dimitra, Hainzl Stefan, Murauer Eva M, Marinkovich M Peter, Platenburg Gerard, Hausser Ingrid, Wally Verena, Ritsema Tita, Koller Ulrich, Haisma Elisabeth M, Nyström Alexander

Abstract excerpt

Dystrophic epidermolysis bullosa (DEB) is a blistering skin disease caused by mutations in the gene COL7A1 encoding collagen VII. DEB can be inherited as recessive DEB (RDEB) or dominant DEB (DDEB) and is associated with a high wound burden. Perpetual cycles of wounding and healing drive fibrosis in DDEB and RDEB, as well as the formation of a tumor-permissive microenvironment. Prolonging wound-free episodes by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Collagen Type VII

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epidermolysis Bullosa Dystrophica

Share to Fibrosis

Share to Genetic Therapy

Share to Keratinocytes

Share to Oligonucleotides, Antisense

Share to Primary Cell Culture

Share to Wound Healing

Source

Open in PubMed

Identifiers

PMID: 32946877
DOI: 10.1016/j.jid.2020.08.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.PMID 32946877Read ↗

Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model.Semantic proximity Read ↗

Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis BullosaSemantic proximity Read ↗

COL7A1 Editing via RNA Trans-Splicing in RDEB-Derived Skin Equivalents.Semantic proximity Read ↗

Base edited skin equivalents with clinical potential for ex vivo correction of recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa.Semantic proximity Read ↗

Gene Therapy for Dystrophic Epidermolysis Bullosa.Semantic proximity Read ↗

Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis BullosaSemantic proximity Read ↗

Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

In Vitro Models for the Evaluation of Antisense Oligonucleotides in Skin.Semantic proximity Read ↗

Splice modulation strategy applied to deep intronic variants in COL7A1 causing recessive dystrophic epidermolysis bullosaSemantic proximity Read ↗

Innovative therapeutic strategies for recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

Therapeutic Prospects of Exon Skipping for Epidermolysis Bullosa.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.